J1322 Elosulfase alfa, injection
Also known as: Vimizim, elosulfase
Elosulfase alfa injection, a sulfatase enzyme for enzyme replacement therapy in mucopolysaccharidosis type IVa.
In Plain Language
Replacement enzyme for rare genetic disease
Clinical Context
Used for enzyme replacement therapy in patients with mucopolysaccharidosis type IVa to improve motor development and skeletal function.
RVU Information
CPT J1322 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J1322?
CPT J1322 (Elosulfase alfa, injection) is a J Codes (Drugs) code. Elosulfase alfa injection, a sulfatase enzyme for enzyme replacement therapy in mucopolysaccharidosis type IVa.
How is J1322 administered?
CPT J1322 is administered by a healthcare provider, typically via injection or infusion. Used for enzyme replacement therapy in patients with mucopolysaccharidosis type IVa to improve motor development and skeletal function. It is used by Genetics, Internal Medicine, Pediatrics.
When is CPT J1322 used?
Used for enzyme replacement therapy in patients with mucopolysaccharidosis type IVa to improve motor development and skeletal function.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.